ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2026
Association Between Low-Dose Aspirin Use and Early Renal Injury Biomarkers in Patients with Type 2 Diabetes Mellitus: A Retrospective Matched Cohort Study.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Microalbuminuria and urine albumin-to-creatinine ratio (UACR) are important markers for early diabetic kidney disease (DKD) in patients with type 2 diabetes mellitus (T2DM). Aspirin (acetylsalicylic acid; ASP) has been associated with anti-inflammatory and metabolic effects in patients with T2DM. This study investigated the association between low-dose ASP use and renal injury markers in patients with T2DM. Methods: A retrospective matched cohort study was conducted in 60 Taiwanese patients with T2DM. Patients receiving low-dose ASP (100 mg/day) were matched 1:1 with controls according to sex, age, height, weight, body mass index, and duration of diabetes. Metabolic outcomes and renal injury markers, including serum creatinine, urine microalbumin, and urine albumin-to-creatinine ratio (UACR), were evaluated during follow-up. Results: Compared with the DM group, the ASP group demonstrated lower HbA1c and total cholesterol levels during follow-up. In renal outcome analysis, urine microalbumin levels were significantly lower in the ASP group than in the DM group at follow-up (p = 0.039). A trend toward improved UACR was also observed in the ASP group. Conclusion: Low-dose ASP use was associated with favorable changes in glycemic control and early renal injury markers in patients with T2DM. Lower urine microalbumin levels and a trend toward improved UACR were observed in the ASP group during follow-up. Although microalbuminuria may be influenced by multiple metabolic and cardiovascular factors, the present findings suggest that low-dose ASP therapy may have potential metabolic and renal associations in patients with T2DM. Further prospective studies are warranted to validate these findings and to explore the underlying mechanisms and their clinical relevance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.